NCT00002415已完成2 期
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 24
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to add PMPA Prodrug (a new anti-HIV drug) to an anti-HIV drug combination taken by patients who have taken anti-HIV drugs in the past. Genetic response will be studied.
详细描述
Prior to study entry patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs. PMPA Prodrug or placebo is added to current antiretroviral regimens, and is administered in one of three dosing regimens. Patients randomized to receive placebo are eligible to receive open-label PMPA Prodrug for the remainder of the 48-week study period after at least 24 weeks post randomization.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You may be eligible for this study if you:
- •Are HIV-positive.
- •Have an HIV count of 400 - 50,000 copies/ml.
- •Are expected to live for at least 1 year.
- •Have been taking the same anti-HIV drug combination (made up of no more than 3 anti-HIV drugs) for at least 8 weeks prior to study entry.
- •Are at least 18 years old.
- •Agree to use effective methods of birth control during the study.
排除标准
- •You will not be eligible for this study if you:
- •Have taken medications for certain infections within 15 days prior to study entry.
- •Have a history of cancer, except Kaposi's sarcoma (KS) or skin cancer.
- •Develop a new AIDS-related condition within 30 days of study entry.
- •Have certain serious medical conditions, including severe nausea, vomiting, or other stomach problems that make you unable to take medications by mouth.
- •Have received a vaccine within 30 days prior to study entry.
- •Have taken certain medications, including those that may affect your kidneys.
- •Abuse alcohol or drugs.
- •Are pregnant.
研究者
研究点 (24)
Loading locations...
相似试验
已完成
1 期
A Study of PMPA in HIV-Infected PatientsHIV InfectionsNCT00002180Gilead Sciences
已完成
2 期
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination TherapyHIV InfectionsNCT00004985Agouron Pharmaceuticals75
已完成
不适用
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive PatientsHIV InfectionsNCT00002426Gilead Sciences390
已完成
3 期
A Study of Indinavir Taken With or Without DMP 266HIV InfectionsNCT00002393Dupont Merck300
终止
2 期
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002418Bristol-Myers Squibb25